Novo Nordisk recalls batches of diabetes drugs

October 25, 2013

Batches of Novo Nordisk's diabetes treatments NovoMix 30 FlexPen and Penfill are being recalled, the European Medicines Agency said on Friday.

"In the affected cartridges the level of insulin may vary between 50 percent and 150 percent of the labelled insulin units, which could lead to or hyperglycaemia," the agency said in a statement.

Only a small percentage of cartridges, 0.14 percent, contain the wrong amount, the Danish company said.

Patients whose products were labelled with numbers from the affected batches should "make an appointment with their doctor or nurse for switching treatment as soon as it is feasible," the EU regulator said.

A spokesperson for the company was not immediately available on Friday afternoon.

Novo Nordisk has almost half the global insulin market, which has grown rapidly in recent years following a rise in the number of people suffering from diabetes, estimated by the World Health Organisation to stand at around 347 million.

Explore further: Danish Novo Nordisk profit surges

Related Stories

Danish Novo Nordisk profit surges

January 31, 2013

Danish pharmaceutical company Novo Nordisk A/S on Thursday reported a 23 percent growth in fourth-quarter net profit on strong sales of diabetic drugs and gave a positive outlook as regulators worldwide begin to approve its ...

Novo Nordisk US shares skid on drug review setback (Update)

February 11, 2013

Shares of Novo Nordisk tumbled Monday after the Danish drugmaker said U.S. regulators need a new study before they can finish their review of two diabetes treatments, a development that could delay approval for several years.

Diabetes drugs helps boost Novo Nordisk in Q2

August 9, 2012

(AP) — Danish pharmaceutical company Novo Nordisk A/S says its net profit grew by 29 percent in the second quarter of 2012, chiefly spurred by strong sales of its new diabetes drugs.

Recommended for you

Post-biotics may help shield obese from diabetes

April 20, 2017

You've heard of pre-biotics and pro-biotics, but now you'll be hearing a lot more about post-biotics. Researchers at McMaster University have begun to identify how post-biotics, or the by-products of bacteria, lower blood ...

Diabetes continues its relentless rise

April 13, 2017

(HealthDay)—Two new studies on diabetes deliver good and bad news, but the overall message is that the blood sugar disease remains a formidable public health burden.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.